Glipohix 513 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. Each sustained-release tablet contains Glimepiride 1 mg, Metformin 500 mg, and Voglibose 0.3 mg, targeting multiple pathophysiological mechanisms involved in hyperglycemia. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial blood glucose spikes. The sustained-release formulation ensures a gradual release of active ingredients, promoting better patient compliance and reducing gastrointestinal side effects commonly associated with immediate-release formulations. Glipohix 513 is indicated as an adjunct to diet and exercise for patients inadequately controlled on monotherapy or dual therapy with these agents. It should be used cautiously in patients with renal or hepatic impairment and contraindicated in those with diabetic ketoacidosis or severe infections. Regular monitoring of blood glucose and renal function is recommended during therapy. This combination therapy offers a comprehensive approach to managing type 2 diabetes by addressing fasting and postprandial hyperglycemia effectively.